Sugi Predict

Sugi Predict / Compounds / SCHEMBL2402192

SCHEMBL2402192

SCHEMBL2402192

CCN1CCN(c2cc[c]nc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 1/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ GAA P10253 2/20 0.49
▸ RAD52 P43351 2/20 0.49
▸ MAPT P10636 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ GFER P55789 1/20 0.49
▸ HRH3 Q9Y5N1 1/20 0.42
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ KDM1A O60341 1/20 0.38
▸ ADRA2A P08913 1/20 0.38
▸ ADRA2B P18089 1/20 0.38
▸ ADRA2C P18825 1/20 0.38
▸ ACHE P22303 1/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ SIGMAR1 Q99720 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17709568 0.81 MAPT (0.44) SMN1; SMN2GAAMAPTKDM4EGFER
SCHEMBL1173015 0.78 CHKA (0.43) SMN1; SMN2GAAMAPTKDM4EGFER
SCHEMBL17316461 0.78 CHKA (0.39) GAAMAPTKDM4EGFERNPC1
SCHEMBL188197 0.77 CHRNA7 (0.66) CHRNA7SMN1; SMN2GAARAD52MAPT
SCHEMBL4461799 0.77 CHKA (0.42) SMN1; SMN2GAAMAPTKDM4EGFER
SCHEMBL6889419 0.75 GAA (0.54) CHRNA7SMN1; SMN2GAARAD52MAPT
SCHEMBL2400015 0.74 GFER (0.51) SMN1; SMN2GAAMAPTKDM4EGFER
SCHEMBL1515215 0.74 LMNA (0.47) SMN1; SMN2GAAMAPTKDM4ENPC1
SCHEMBL2402319 0.72 HIF1A (0.35) KMT2ACYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL2401650 0.72 AKR1C3 (0.50) SMN1; SMN2MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10842803-B2 Imidazopyridines Syk inhibitors Kronos Bio, Inc. (US) 2020-11-24 — — US claimed
US-20190117679-A1 IMIDAZOPYRIDINES SYK INHIBITORS Kronos Bio, Inc. 2019-04-25 — — US claimed
US-20180065969-A1 THERAPEUTIC AGENT OF ACUTE MYELOID LEUKEMIA CONTAINING 1,3,7-TRISUBSTITUTED 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDINE-2(1H)-ONE DERIVATIVES KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-03-08 — — US claimed
EP-2545052-B1 IMIDAZOPYRIDINES SYK INHIBITORS GILEAD CONNECTICUT INC (US) 2014-11-12 — — EP claimed
US-20140148430-A1 IMIDAZOPYRIDINES SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2014-05-29 — — US claimed
US-20130210802-A1 IMIDAZOPYRIDINES SYK INHIBITORS Gilead Connecticut, Inc (US) 2013-08-15 — — US claimed
EP-2545052-A1 IMIDAZOPYRIDINES SYK INHIBITORS Gilead Connecticut, Inc. (US) 2013-01-16 — — EP claimed
WO-2011112995-A1 IMIDAZOPYRIDINES SYK INHIBITORS GILEAD SCIENCES, INC. (US) 2011-09-15 — — WO claimed
US-10842803-B2 Imidazopyridines Syk inhibitors Kronos Bio, Inc. (US) 2020-11-24 — — US disclosed
US-20190117679-A1 IMIDAZOPYRIDINES SYK INHIBITORS Kronos Bio, Inc. 2019-04-25 — — US disclosed
US-10092583-B2 Imidazopyridines Syk inhibitors GILEAD CONNECTICUT, INC. (US) 2018-10-09 — — US disclosed
US-20170095490-A1 IMIDAZOPYRIDINES SYK INHIBITORS Kronos Bio, Inc. 2017-04-06 — — US disclosed
US-9562056-B2 Imidazopyridines Syk inhibitors GILEAD CONNECTICUT, INC. (US) 2017-02-07 — — US disclosed
EP-2545052-B1 IMIDAZOPYRIDINES SYK INHIBITORS GILEAD CONNECTICUT INC (US) 2014-11-12 — — EP disclosed
US-20140148430-A1 IMIDAZOPYRIDINES SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2014-05-29 — — US disclosed
US-20130210802-A1 IMIDAZOPYRIDINES SYK INHIBITORS Gilead Connecticut, Inc (US) 2013-08-15 — — US disclosed
EP-2545052-A1 IMIDAZOPYRIDINES SYK INHIBITORS Gilead Connecticut, Inc. (US) 2013-01-16 — — EP disclosed
CN-102741256-A Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase HANMI PHARM IND CO LTD 2012-10-17 — — CN disclosed
WO-2011112995-A1 IMIDAZOPYRIDINES SYK INHIBITORS GILEAD SCIENCES, INC. (US) 2011-09-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190117679-A1 IMIDAZOPYRIDINES SYK INHIBITORS SYK, BTK, ZAP70 CHRNA7 4211/4885SMN1; SMN2 2404/4885GAA 430/4885
US-10092583-B2 Imidazopyridines Syk inhibitors SYK, BTK, ZAP70 CHRNA7 4211/4885SMN1; SMN2 2404/4885GAA 430/4885
US-20170095490-A1 IMIDAZOPYRIDINES SYK INHIBITORS SYK, BTK, ZAP70 CHRNA7 4211/4885SMN1; SMN2 2404/4885GAA 430/4885
US-20180065969-A1 THERAPEUTIC AGENT OF ACUTE MYELOID LEUKEMIA CONTAINING 1,3,7-TRISUBSTITUTED 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDINE-2(1H)-ONE DERIVATIVES GAK, DCK, NRAS CHRNA7 4079/4885SMN1; SMN2 4036/4885GAA 4009/4885
US-20130210802-A1 IMIDAZOPYRIDINES SYK INHIBITORS SYK, BTK, ZAP70 CHRNA7 4145/4885SMN1; SMN2 2443/4885GAA 433/4885
US-20140148430-A1 IMIDAZOPYRIDINES SYK INHIBITORS SYK, BTK, ZAP70 CHRNA7 4145/4885SMN1; SMN2 2443/4885GAA 433/4885
US-10842803-B2 Imidazopyridines Syk inhibitors SYK, BTK, ZAP70 CHRNA7 4211/4885SMN1; SMN2 2404/4885GAA 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.